Cargando…
A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer
BACKGROUND: A germline deletion in the BIM (BCL2L11) gene has been shown to impair the apoptotic response to tyrosine kinase inhibitors (TKIs) in vitro but its association with poor outcomes in TKI-treated non-small cell lung cancer (NSCLC) patients remains unclear. We conducted a systematic review...
Autores principales: | Soh, Sheila X., Siddiqui, Fahad J., Allen, John C., Kim, Go Woon, Lee, Jae Cheol, Yatabe, Yasushi, Soda, Manabu, Mano, Hiroyuki, Soo, Ross A., Chin, Tan-Min, Ebi, Hiromichi, Yano, Seiji, Matsuo, Keitaro, Niu, Xiaomin, Lu, Shun, Isobe, Kazutoshi, Lee, Jih-Hsiang, Yang, James C., Zhao, Mingchuan, Zhou, Caicun, Lee, June-Koo, Lee, Se-Hoon, Lee, Ji Yun, Ahn, Myung-Ju, Tan, Tira J., Tan, Daniel S., Tan, Eng-Huat, Ong, S. Tiong, Lim, Wan-Teck |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522319/ https://www.ncbi.nlm.nih.gov/pubmed/28467813 http://dx.doi.org/10.18632/oncotarget.17102 |
Ejemplares similares
-
Multi-Agent Chemotherapy Overcomes Glucocorticoid Resistance Conferred by a BIM Deletion Polymorphism in Pediatric Acute Lymphoblastic Leukemia
por: Soh, Sheila Xinxuan, et al.
Publicado: (2014) -
Overcoming imatinib resistance conferred by the BIM deletion polymorphism in chronic myeloid leukemia with splice-switching antisense oligonucleotides
por: Liu, Jun, et al.
Publicado: (2017) -
Multiparametric MRI in Active Surveillance of Prostate Cancer: An Overview and a Practical Approach
por: Lee, Chau Hung, et al.
Publicado: (2021) -
Association of clinical factors with survival outcomes in laryngeal squamous cell carcinoma (LSCC)
por: Fong, Pei Yuan, et al.
Publicado: (2019) -
Not just gRASping at flaws: Finding vulnerabilities to develop novel therapies for treating KRAS mutant cancers
por: Ebi, Hiromichi, et al.
Publicado: (2014)